CEONEWS.Tv

Tonix Pharmaceuticals is Developing New Formulations to Treat Central Nervous System Conditions

Tonix is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions that may be safer and more effective than currently available treatments. They use ongoing advances in science and medicine to search for potential therapeutic solutions among already existing prescription pharmaceutical agents that have been successfully used in patients for other conditions. They create new dose formulations for these agents with the intent to developing products that are optimized for the new therapeutic uses that we target.

Dr. Seth Lederman, CEO

Dr. Seth Lederman is a physician, scientist, and specialty pharmaceuticals entrepreneur. Prior to founding TONIX, from 2007-2008 Dr. Lederman co-founded and was a managing partner of Konanda Pharma Partners, LLC and Konanda Pharma Fund I, LP. He co-founded and served as director and chairman of its wholly-owned operating companies Validus and Fontus Pharmaceuticals Inc., which market Equetro® (carbamazepine – Extended Release), Marplan® (isocarboxazid) and Rocaltrol® (calcitriol). In 2000 Dr. Lederman founded Targent Pharmaceuticals to develop late-stage oncology drugs including pure-isomer levofolinic acid, which was sold to Spectrum Pharmaceuticals and is now FDA-approved and marketed as Fusilev® for colorectal cancer. In 1998 Dr. Lederman co-founded Vela Pharmaceuticals, which developed several drugs for central nervous system disorders, including VLD-cyclobenzaprine. 

A member of the faculty of Columbia University’s College of Physicians and Surgeons since 1985, Dr. Lederman maintains an appointment as Associate Professor. At Columbia, he was an NIH Physician-Scientist from 1985-1990. Dr. Lederman became an Associate Professor with tenure in 1996 and Director of the Laboratory of Molecular Immunology in 1997. From 1988 to 2002, he directed basic science research at Columbia in molecular immunology, infectious diseases and the development of therapeutics for autoimmune diseases. Dr. Lederman has authored numerous scientific articles, and has been issued several patents for drug development technologies. 

Dr. Lederman’s fundamental research on the CD40-Ligand (CD154) elucidated the molecular basis of T cell helper function and led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection in collaboration with Biogen-IDEC and CellTech/UCB. The successful defense of his CD154 patents established important precedents defining the relationship between therapeutics and molecular targets. In collaboration with Prof. David Baltimore (then at Rockefeller University and later MIT), Dr. Lederman identified and functionally characterized the CD40 signaling molecule, TRAF-3. Dr. Lederman’s earlier research efforts in HIV contributed to understanding how the V3 loop of HIV gp120 affected fusion with CD4 cell membranes, an early and essential event in viral entry and infection. 

Dr. Lederman earned an AB from Princeton in Chemistry cum laude in 1979 and an MD from Columbia University’s College of Physicians and Surgeons in 1983. He trained in internal medicine and rheumatology at Columbia’s Presbyterian Hospital, serving as an attending physician in its Edward Daniels Arthritis and Autoimmunity Clinic from 1988-1996.

Interview with CEO Dr. Seth Lederman

Neurometrix Enters Managed Care Market With WellMed As Client

NeuroMetrix is a science-based health care company improving patient care through NeuroTechnology.

Medical Devices

• Based in Waltham, MA
• Public since 2004. Listed on Nasdaq as: NURO

Focused on Point-of-Care Nerve Testing

• Created concept and market
• Market leader - 10 years plus, 5 million nerves tested, 1.5 million patients
• Premier R&D capability in the space, proprietary technology, Intellectual Property

Two Aspects to the Business

• Emerging business in diabetes care
• Established business in neurodiagnostics
  •    Founded in 1996 as MIT/Harvard Medical School spinoff
    • Orthopedics (hand surgery), primarily diagnosis of carpal tunnel syndrome
    • General purpose nerve testing within primary care

Shai N. Gozani, M.D., Ph.D.

President, Chief Executive Officer and Director

Dr. Gozani founded NeuroMetrix in 1996 and currently serves as Chairman of the board of directors and as President and Chief Executive Officer. Prior to forming the company, Dr. Gozani completed a neurophysiology research fellowship in the laboratory of Dr. Gerald Fischbach at Harvard Medical School. Dr. Gozani holds a B.A. degree in Computer Science, an M.S. degree in Biomedical Engineering and a Ph.D. in Neurobiology, from the University of California, Berkeley. He also received an M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology at M.I.T. 

Interview with Dr. Shai N. Gozani, M.D., Ph.D.

NURO-MC.mp3

(download)

Click here to download:

NURO-MC.mp3 (5.96 MB)

TMEN Strategically Positioned Within The Trillion Dollar Energy Market!

ThermoEnergy Corporation’s mission is to become a significant force within the global municipal and industrial wastewater and power generation industries. They are focused on helping clients succeed with efficient, cost effective wastewater treatment and power generation technologies.

Cary Bullock, President & CEO

Cary Bullock has been in the energy & cleantech industry for more than 25 years and is a graduate of Amherst College and MIT. He is currently Chairman & CEO and on the Board Member of ThermoEnergy Corporation, a company involved in the development and sale of clean water and clean energy technologies. Related, he serves as the senior officer in Castion Corporation and ThermoEnergy Power Systems, two ThermoEnergy subsidiaries. He is a Board Member of Boyd Technologies. He has been a founder, principal and/or senior executive for several energy ventures. These include GreenFuel Technology Corporation (Board Member, former President, CEO, and VP Business Development), Excelergy (Board Member, co-founder, Chairman & CEO), Hillside Investment (Chairman & CEO, seed investor in Excelergy, Capital-E (investor), Dyax (investor), FPL Energy Services, and consultant to many other ESCOs), FPL Energy Services (Board Member and assisted in founding), NS Power Services (Board Member and assisted in founding), KENETECH (VP, President of KENETECH Energy Management), Econoler/USA (co-founder, Chairman & CEO), and Xenergy (a principal owner, Board member, and VP Engineering and Operations). In addition, he has been an advisor to several early stage companies and entrepreneurs. 

Mr. Bullock has written and spoken extensively on energy and cleantech and has received numerous honors in the field. He has been a member of Business Week’s Energy & Environment Council (2007-8). In 2001, he was named one of the 50 top IT managers in the energy industry by Pratts Energy. In 2002 and 2007, Mr. Bullock was a finalist for the Enerst & Young New England Entrepreneur of the Year. In 2000, he was named one of the 100 most influential individuals in the gas and electric business in the 20th century by Harts Energy Markets in their special Century of Power retrospective on the industry for his contributions to the International Performance Measurement and Verification Protocol which defined methods of assessing energy savings for performance contracting (DOE, December 1997). 

Companies where Bullock was a principal, founder and/or senior executive have also received numerous awards including Artemis Project™ Top 50 Water Company (Castion 2010), AlwaysOn Northeast Top 100 Companies, (GreenFuel 2008); SBANE’s New England Innovation Award (Finalist) (GreenFuel, 2007); Red Herring Top 100, recognizing the top private and publicly held companies (Excelergy: 2001, 2002, 2003, GreenFuel: 2006); Platts Energy, Global award for “Emissions Energy Project of the Year”, jointly with Arizona Public Service (GreenFuel: 2006) for project making biodiesel and ethanol from power plant emissions; American Society for Competitiveness (ASC), Medallion for “Energy Business Competitiveness through Financial Prowess and Global Environmental and Technology Leadership in Industrial Power Markets” (Greenfuel: 2005, 2006, 2007); Frost & Sullivan, Award for “Technology Innovation of the Year” (Greenfuel: 2006); GoGreen Award (GreenFuel 2005); Forbes B2B, best of the web (Excelergy: 2002, 2003); Upside Magazine, Upside Hot 100 (Excelergy: 2002); Utility CIS/CRM Consortium, Utility Award for CIS/CRM Excellence (Excelergy: CIS Initiative – Europe 2003); Power & Gas Marketing, Premium Product Award (Excelergy: 2002); Platts/ BusinessWeek, Finalist for Global Energy Award (Excelergy: 2002).

Interview with Cary Bullock, CEO

Apricus Bioscience's CEO Interviewed Concerning "Vitaros"

Apricus Bio is a San Diego-based, revenue-generating, specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes. 

Revenues and growth are driven from the sales of the Company's commercial products and out-licensing in certain territories of its product pipeline and NexACT® technology. The company's pipeline includes Vitaros®, approved in Canada for the treatment of erectile dysfunction, Totect the only drug approved in the US for the treatment of anthracycline extravasation, as well as compounds in development from pre-clinical through pre-registration, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer Healthcare. 

The Company also expects to develop and/or acquire and then bring to market additional pharmaceutical products in areas of care that will benefit patient needs worldwide.

Bassam Damaj, Ph.D

Chairman of the board, President, & Chief Executive Officer  Dr. Damaj was the co-founder and former Chief Scientific Officer of Bio-Quant, and served in that capacity since its inception in 1999. Prior to Bio-Quant, Dr. Damaj served as President & Chief Executive Officer of BioSignature Diagnostics, Inc. He also served as the Group Leader for the Office of New Target Intelligence and a Group Leader for immunological and inflammatory disease programs at Tanabe Research Laboratories, U.S.A., Inc.

Previous appointments included Pharmacopeia Inc., a New Jersey based company where Dr. Damaj   served as a senior scientist and a member of the senior staff board of the drug discovery department. He was also a visiting scientist at Genentech, Inc., Pfizer Inc. and the NIH (NIAID). Dr. Damaj is the founder of Celltek Biotechnology, Mina Holdings, BioSignature Diagnostics and R&D Healthcare Inc. He holds numerous patents in this field and authored numerous peer reviewed scientific publications, and is the author of the Immunological Reagents and Solutions reference book. Dr. Damaj served on several scientific advisory boards of biopharmaceuticals including Celltek, Virocell and Microislet, Inc. He is the holder of the U.S. Congress Award for the development of the first Anthrax Diagnostic Blood Test for the United States in 2003. He also represented the State of California on the Congressional Scientific Liaison Committee in 2002. Dr. Damaj holds a Ph.D. in Immunology/Microbiology, a postdoctoral fellowship in Molecular Oncology and an MBA in Healthcare. He has been involved with over seven drug candidates currently in clinical trials for a variety of diseases. 

Because Dr. Damaj brings numerous years of biotechnology and pharmaceutical experience in drug discovery and development to the company, he was appointed to serve as President and Chief Executive Officer in December 2009. Additionally he was made a member of the Board in 12/09 and elected as Chairman of the Board in October 2010.

Interview with Dr. Bassam Damaj Phd., CEO